Blog
RSS FeedPosted by Michael Wonder on 14 May 2020
China NMPA approves Optune for the treatment of newly diagnosed and recurrent glioblastoma
13 May 2020 - Optune is the first innovative treatment for glioblastoma approved in China in over 15 years. ...
Posted by Michael Wonder on 11 May 2020
China approves Novartis' multiple sclerosis treatment Mayzent
9 May 2020 - Chinese regulators have approved Novartis' Mayzent to treat relapsing multiple sclerosis in adults, the Swiss drug ...
Posted by Michael Wonder on 11 May 2020
OIA response: medicines from China
11 May 2020 - PHARMAC responds as OIA request, dated 27 February 2020, asking for a list of medications made ...
Posted by Michael Wonder on 04 May 2020
China National Medical Products Administration approves Doptelet (avatrombopag) for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure
30 April 2020 - First approval for Doptelet in China and first-ever treatment for this indication in China. ...
Posted by Michael Wonder on 25 Apr 2020
Maker of drug touted as coronavirus cure accuses China of gouging
24 April 2020 - Hydroxychloroquine controversially pushed by Trump as COVID-19 remedy. ...
Posted by Michael Wonder on 14 Apr 2020
China National Medical Products Administration approves BeiGene’s tislelizumab for patients with previously treated locally advanced or metastatic urothelial carcinoma
10 April 2020 - Second approval of tislelizumab in China, first in solid tumour ...
Posted by Michael Wonder on 13 Apr 2020
Astellas announces acceptance of Xospata (gilteritinib) for regulatory review in China by the National Medical Products Administration
10 April 2020 - Astellas announced today a new drug application for the oral once-daily therapy Xospata (gilteritinib), for the treatment ...
Posted by Michael Wonder on 24 Mar 2020
An update on the 2020 annual meeting in Beijing, China
20 March 2020 - Based on the balance of the evidence before the Board, and with the strong support of our ...
Posted by Michael Wonder on 23 Mar 2020
Hansoh Pharma’s Ameile (almonertinib) receives marketing authorisation in China for second-line treatment for patients with EGFR T790 mutation non-small cell lung cancer
19 March 2020 - Hansoh Pharmaceutical Group announced that the National Medical Products Administration has granted marketing authorisation for Ameile ...
Posted by Michael Wonder on 16 Mar 2020
Chinese official warns against U.S. effort to limit foreign medicine supplies
17 March 2020 - A Chinese official on Monday warned that a push by the White House to reduce U.S. ...
Posted by Michael Wonder on 16 Mar 2020
Reliance on China for medicines an emergency
16 March 2020 - The United States has declared a national emergency as a result of the spread of COVID-19. ...
Posted by Michael Wonder on 12 Mar 2020
Coronavirus spurs U.S. efforts to end China’s chokehold on drugs
11 March 2020 - The Trump administration says the U.S. is too dependent on China for vital drugs. But it’s unclear ...
Posted by Michael Wonder on 10 Mar 2020
Global companies expand the reach of their cancer drugs in China
10 March 2020 - While much of the world is understandably focused on the new coronavirus’s emergence in China, three ...
Posted by Michael Wonder on 02 Mar 2020
Erbitux approved for first-line use in China in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
2 March 2020 - Approval is for Erbitux in combination with platinum-based therapy with 5-fluorouracil for the first-line treatment of R/M ...
Posted by Michael Wonder on 15 Feb 2020
China National Medical Products Administration grants approval of Roche’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
14 February 2020 - This marks the first approval for a Tecentriq-based therapy in China, less than a year after the ...